Genocea Biosciences (GNCA) Competitors Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends GNCA vs. SCPS, ARDS, STAB, EVLO, AMPE, CMRA, EFTR, ONCSQ, ATNFW, and LBPSWShould you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Scopus BioPharma (SCPS), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Evelo Biosciences (EVLO), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), eFFECTOR Therapeutics (EFTR), OncoSec Medical (ONCSQ), 180 Life Sciences (ATNFW), and 4D pharma (LBPSW). These companies are all part of the "pharmaceutical products" industry. Genocea Biosciences vs. Scopus BioPharma Aridis Pharmaceuticals Statera Biopharma Evelo Biosciences Ampio Pharmaceuticals Comera Life Sciences eFFECTOR Therapeutics OncoSec Medical 180 Life Sciences 4D pharma Scopus BioPharma (NASDAQ:SCPS) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, community ranking, valuation and profitability. Which has stronger earnings & valuation, SCPS or GNCA? Scopus BioPharma has higher earnings, but lower revenue than Genocea Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/AGenocea Biosciences$1.91M0.00-$33.20M-$0.61N/A Is SCPS or GNCA more profitable? Scopus BioPharma's return on equity of 0.00% beat Genocea Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Genocea Biosciences N/A -182.88%-62.76% Do insiders and institutionals hold more shares of SCPS or GNCA? 0.6% of Genocea Biosciences shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, SCPS or GNCA? Scopus BioPharma has a beta of -0.01, indicating that its stock price is 101% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Does the media prefer SCPS or GNCA? In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Genocea Biosciences Neutral Does the MarketBeat Community believe in SCPS or GNCA? Genocea Biosciences received 386 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 57.57% of users gave Genocea Biosciences an outperform vote. CompanyUnderperformOutperformScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo VotesGenocea BiosciencesOutperform Votes38857.57% Underperform Votes28642.43% Do analysts recommend SCPS or GNCA? Given Genocea Biosciences' higher probable upside, analysts plainly believe Genocea Biosciences is more favorable than Scopus BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scopus BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AGenocea Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A SummaryScopus BioPharma and Genocea Biosciences tied by winning 5 of the 10 factors compared between the two stocks. Ad Weiss RatingsProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. Get Genocea Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNCA vs. The Competition Export to ExcelMetricGenocea BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$6,000.00$3.12B$5.02B$8.44BDividend YieldN/A1.76%7.49%4.16%P/E Ratio0.0015.17127.0816.62Price / SalesN/A308.201,683.1877.41Price / CashN/A144.3536.9033.53Price / BookN/A4.004.585.21Net Income-$33.20M-$42.08M$113.81M$223.74M Genocea Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastSCPSScopus BioPharmaN/A$0.00flatN/AN/A$17,000.00N/A0.009Gap DownARDSAridis Pharmaceuticals0.8992 of 5 stars$0.00+50.0%$2.00+666,566.7%-99.8%$16,000.00$3.09M0.0030Gap UpSTABStatera BiopharmaN/A$0.00-33.3%N/A-97.0%$11,000.00$1.49M0.0020Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/A-99.9%$6,000.00N/A0.00120AMPEAmpio PharmaceuticalsN/A$0.00flatN/A-99.9%$3,000.00N/A0.0020CMRAComera Life SciencesN/A$0.00-50.0%N/AN/A$3,000.00$630,000.000.002Gap DownEFTReFFECTOR TherapeuticsN/A$0.00flat$24.00+5,999,900.0%-100.0%$2,000.00$3.55M0.0010ONCSQOncoSec MedicalN/A$0.00+∞N/AN/A$1,000.00N/A0.0040Gap UpATNFW180 Life SciencesN/A$0.01+15.0%N/A+0.0%$0.00N/A0.007Gap DownLBPSW4D pharmaN/A$0.04-25.7%N/AN/A$0.00$522,000.000.00N/AGap Down Related Companies and Tools Related Companies SCPS Competitors ARDS Competitors STAB Competitors EVLO Competitors AMPE Competitors CMRA Competitors EFTR Competitors ONCSQ Competitors ATNFW Competitors LBPSW Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNCA) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genocea Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
